APGE NASDAQ
Waltham, MA 02453
US
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| McKenna Mark C. | D-Return | 20,000 | — | 2026-09-03 |
| McKenna Mark C. | D-Return | 10,370 | $43.85 | 2026-09-03 |
| McKenna Mark C. | D-Return | 14,461 | $41.66 | 2026-09-03 |
| McKenna Mark C. | D-Return | 7,657 | $85.00 | 2026-09-03 |
| JONES WILLIAM A JR | D-Return | 34,824 | — | 2026-09-03 |